JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on October 24, 2003
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
278/43/42178    most recent
M304980200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pandini, G.
Right arrow Articles by Belfiore, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pandini, G.
Right arrow Articles by Belfiore, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Papers In Press, published online ahead of print July 24, 2003
J. Biol. Chem, 10.1074/jbc.M304980200
Submitted on May 13, 2003
Revised on July 17, 2003
Accepted on July 24, 2003

Differential gene expression induced by insulin and IGF-ii through the insulin receptor isoform A

Giuseppe Pandini, Enzo Medico, Enrico Conte, Laura Sciacca, Riccardo Vigneri, and Antonino Belfiore

Department of Clinical and Experimental Medicine, University of Catania, Catanzaro, Catanzaro 88100

Corresponding Author: belfiore{at}unicz.it

The human insulin receptor (IR) exists in two isoforms (IR-A and IR-B). IR-A is a short isoform, generated by the skipping of exon 11, a small exon encoding for 12 aminoacid residues at the carboxyl terminus of the IR a-subunit. Recently, we found that IR-A is the predominant isoform in fetal tissues and malignant cells and binds with a high affinity not only insulin but also IGF-II. In order to investigate whether the activation of IR-A by the two ligands differentially activate post-receptor molecular mechanisms, we studied gene expression in response to IR-A activation by either insulin or IGF-II, using microarray technology. To avoid the interfering effect of the IGF-IR, IGF-II binding to the IR-A was studied in IGF-IR deficient murine fibroblasts (R- cells) transfected with the human IR-A cDNA (R-/IR-A cells). Gene expression was studied at 0.5, 3 and 8 hr. We found that 214 transcripts were similarly regulated by insulin and IGF-II while 45 genes were differentially transcribed. Eighteen of these differentially regulated genes were responsive to only one of the two ligands (12 to insulin and 6 to IGF-II). Twenty-seven transcripts were regulated by both insulin and IGF-II but a significant difference between the two ligands was present at least in one time point. Interestingly, IGF-II was a more potent and/or persistent regulator than insulin for these genes. Results were validated by measuring the expression of 12 genes by quantitative Real-Time RT-PCR. In conclusion, we show that insulin and IGF-II, acting via the same receptor, may differentially affect gene expression in cells. These studies provide a molecular basis for understanding some of the biological differences between the two ligands and may help to clarify the biological role of IR-A in embryonic/fetal growth and the selective biological advantage that malignant cells producing IGF-II may acquire via IR-A overexpression.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
U. Hiden, E. Glitzner, M. Ivanisevic, J. Djelmis, C. Wadsack, U. Lang, and G. Desoye
MT1-MMP Expression in First-Trimester Placental Tissue Is Upregulated in Type 1 Diabetes as a Result of Elevated Insulin and Tumor Necrosis Factor-{alpha} Levels
Diabetes, January 1, 2008; 57(1): 150 - 157.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Jensen, B. Hansen, P. De Meyts, L. Schaffer, and B. Urso
Activation of the Insulin Receptor by Insulin and a Synthetic Peptide Leads to Divergent Metabolic and Mitogenic Signaling and Responses
J. Biol. Chem., November 30, 2007; 282(48): 35179 - 35186.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
L.E. Diaz, Y-C. Chuan, M. Lewitt, L. Fernandez-Perez, S. Carrasco-Rodriguez, M. Sanchez-Gomez, and A. Flores-Morales
IGF-II regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor
Mol. Hum. Reprod., August 1, 2007; 13(8): 567 - 576.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S. Yakar, N. P. Nunez, P. Pennisi, P. Brodt, H. Sun, L. Fallavollita, H. Zhao, L. Scavo, R. Novosyadlyy, N. Kurshan, et al.
Increased Tumor Growth in Mice with Diet-Induced Obesity: Impact of Ovarian Hormones
Endocrinology, December 1, 2006; 147(12): 5826 - 5834.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
G. PANDINI, E. CONTE, E. MEDICO, L. SCIACCA, R. VIGNERI, and A. BELFIORE
IGF-II Binding to Insulin Receptor Isoform A Induces a Partially Different Gene Expression Profile from Insulin Binding
Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 450 - 456.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.